News

Patient Interviews

Press Releases

Zhongmou Therapeutics has completed a new funding round worth tens of millions of RMB to accelerate its global expansion in ophthalmic gene therapy.

Wuhan, China – July 28, 2025 – Zhongmou Therapeutics (Wuhan) Co., Ltd. (“Zhongmou Therapeutics”), a global clinical-stage innovator in ophthalmic gene therapy, today announced the signing of a new financing agreement worth tens of millions of RMB. Leading and participating investors in this round include some of China’s most prominent investment institutions. Additional investors are currently in discussions to join, and the total financing amount is expected to further increase....

Zhongmou Announces Groundbreaking Clinical Data for ZM-02 and ZM-01 at ARVO and ASGCT 2025, Recognized with ARVO Foundation Travel Grant

[California, USA, and CHINA, April 18, 2025] Zhongmou Therapeutics ("Zhongmou"), a global clinical-stage gene therapy company focused on providing life-changing treatments to reverse or prevent blindness, today announced three significant milestones:...

Zhongmou Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ZM-02 Optogenetic Therapy to Treat Retinitis Pigmentosa

Zhongmou Therapeutics ("Zhongmou"), a global clinical-stage genomic medicine company bringing life-changing treatment to reverse or prevent blindness, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation ...

News

合肥市武汉大学创新技术研究院组织视网膜疾病基因治疗创新药项目双需对接会

Zhongmou Therapeutics Announces Preliminary Clinical Data From First-in-human Clinical Trail Of Optogenetic Gene Therapy In Retinitis Pigmentosa Patients

中眸医疗即将启动针对晚期视网膜色素变性的基因治疗临床试验

Visual Function Restoration With A Highly Sensitive and Fast Channelrhodopsin In Blind Mice

海特生物成功增资入股中眸医疗科技（武汉）有限公司

©Zhongmou Therapeutics. All rights reserved